Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Ahmad M Mansour1
Maha Shahin2
Peter K Kofoed3
Maurizio B Parodi4
Michel Shami5
Stephen G Schwartz6
Collaborative Anti-VEGF Ocular Vascular Complications Group

Department of Ophthalmology, 1American University of Beirut, Beirut, Lebanon, Rafic Hariri University Hospital, Beirut, Lebanon; 2Mansoura University, Mansoura City, Egypt; 3Glostrup Hospital, University of Copenhagen, Denmark, National Eye Clinic, Kennedy Center, Glostrup, Denmark; 4University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy; 5Texas Tech University Health Sciences Center, Lubbock, TX, USA; 6Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Naples and Miami, FL, USA

Aim: To record ocular vascular events following injections of vascular endothelium growth factor (VEGF) antagonists.

Methods: Collaborative multicenter case series (48 cases), literature reviews (32 cases), and reports to the FDA (64 cases) of patients that had vascular occlusions during anti-VEGF therapy were collected and analyzed.

Results: A total of 144 cases of ocular vascular events were identified, with these diagnosed a median of 15 days after anti-VEGF injection. The majority of patients had pre-existing risk factors for cardiovascular events and nine patients had a prior history of glaucoma. Mean visual acuity dropped by 6.4 lines with severe visual loss after injection to NLP (five eyes), LP (six eyes), and HM (two eyes). The overall risk of ocular vascular events following a VEGF antagonist injection was 0.108% in the general population and 2.61% in the diabetic population. Mean retinal arterial constriction after intravitreal bevacizumab in 13 eyes was 21% (standard deviation = 27%), and mean retinal venous constriction was 8% (standard deviation = 30%).

Conclusion: Ocular vascular events are rare during anti-VEGF therapy, but can lead to severe visual loss and may be caused by a number of factors including the vasoconstrictor effect of the drug, a post-injection rise of intraocular pressure, patient stress as a result of the procedure, and the patient’s natural history of underlying ocular or systemic diseases. The diabetic population appears to have a tendency towards ocular vascular occlusions.

Keywords: Bevacizumab, retinal artery occlusion, retinal vein occlusion, retinal capillary occlusion, ranibizumab

Introduction

Vascular endothelial growth factor (VEGF) has vasodilatory effects so is used by vascular surgeons to treat ischemic diseases,1 and intravitreal VEGF antagonists are now being used by ophthalmologists to treat various ischemic retinal disorders.2,3 Several studies report that fluorescein angiographic findings are absent following the administration of intravitreal bevacizumab or ranibizumab.4–9 Preliminary case series reported by some researchers suggest the possibility of a temporal link between these injections and subsequent retinal vascular events.10–21 In the current study additional data that was contributed by various collaborators and supplemented by the literature22–44 is presented to further analyze the possible relationship between anti-VEGF injections and ocular vascular accidents. Additionally, the current study provides information regarding the characterization of patients developing ocular vascular complications after intravitreal injections of anti-VEGF drugs.
Methods
The current study is a retrospective survey among members of the American Society of Retinal Specialists who were invited to contribute a detailed protocol of cases that had vascular occlusions (central retinal artery occlusion [CRAO], branch retinal artery occlusion [BRAO], capillary occlusion, central retinal vein occlusion [CRVO], branch retinal vein occlusion [BRVO], anterior ischemic optic neuropathy [AION], and ocular ischemic syndrome) following anti-VEGF therapy. This research was approved by the Institutional Research Board (Rafic Hariri University Hospital, an affiliate of the American University of Beirut). Each center received Ethical Committee approval for the use of anti-VEGF for specific use and data analyses. The data collected included risk factors for vascular occlusion (carotid disease, coronary artery disease, systemic hypertension, diabetes mellitus, migraine, smoking, and glaucoma), the intraocular pressure on discharge, and the time period from intravitreal injection to detection of the vascular event. The total number of injections per investigator was also recorded.

A 14-month prospective study was also performed at Mansoura University using intravitreal bevacizumab. This included 42 patients, 33 of whom had proliferative diabetic retinopathy, seven with age-related macular degeneration, and two with central retinal vein occlusion. The study was approved by the Ethical Committee of Mansoura University.

Additionally, all studies in the literature regarding treatments with ranibizumab, bevacizumab, pegaptanib, and aflibercept as listed in PubMed and Scopus prior to August 2011 were searched for reports of adverse effects. As well as this, detailed reports of adverse effects of anti-VEGF medications sent to the FDA prior to April 2011 were retrieved via patientsville.com (for reports submitted from 2006 to 2009) and eHealthme.com (for reports submitted from 2010 to 2011), and retinal vascular events were selected for the current study.

Digital fundus photography and computerized determination of retinal trunk vessel diameters were performed using the previously described software.

For each case the pre- and post-anti-VEGF treatment fundus photographs were analyzed using custom computer software. For each case a grader (PKK) chose at least two artery segments and two vein segments that were deemed the most suitable for analysis based on image quality, contrast, straightness of the vessel, absence of branching, and absence of vessel crossings. Images of these vessel segments taken before and after anti-VEGF treatment were analyzed for each case. Images were considered non-gradable if the image was of poor quality (low contrast), as judged by the grader. When necessary, images were calibrated by scaling them so that they were of equal size. Results were presented as the relative change in vessel diameter following anti-VEGF treatment.

Results
A total of 144 cases were available for this study, which included 32 cases retrieved from the literature, 64 reports to the Food and Drug Administration (FDA), and 48 cases contributed from 22 centers across Africa, America, Asia, and Europe (Tables 1 and 2). Eight of these cases were part of a prospective study at Mansoura University (Mansoura City, Egypt) of 42 patients treated with intravitreal bevacizumab (33 patients with advanced proliferative diabetic retinopathy, seven with choroidal neovascularization, and two with central retinal vein occlusion). From 1665 reports of adverse effects following treatment with ranibizumab, 7167 reports of adverse effects following treatment with bevacizumab, 355 reports of adverse effects following treatment with pegaptanib, and 74 reports of adverse effects following treatment with aflibercept (VEGF Trap), the current study collected data on twelve ranibizumab-, 28 bevacizumab-, and six pegaptanib-related retinal vascular events.

Overall, 30 received ranibizumab, 9 pegaptanib and 106 bevacizumab (of which 13 received systemic bevacizumab, one received intracameral bevacizumab, one received 0.625 mg intravitreal bevacizumab, six received 2.5 mg intravitreal bevacizumab, and 55 received 1.25 mg intravitreal bevacizumab). The patient’s gender was not always specified, but of those patients for whom this was specified there were 53 males and 55 females. In 95 patients, the median age was 67 (range = 0–95 years; mean = 64.5 years). Vascular events were diagnosed a median of 15 days after treatment (n = 56; range = 0–60 days). The median number of prior injections was one (range = 0–34). The right eye was involved in 30 patients, and the left eye in 28 patients (five patients had bilateral events, while the side was not specified for the remainder).

A majority of patients had preexisting risk factors for cardiovascular events. More specifically, diabetes mellitus was documented in a total of 44 patients. There were 37 diabetic patients in the combined group of 80 patients from the collaborative study and the literature review, ie, 46.3% of the combined group had diabetes mellitus. Other systemic disorders of the whole series included systemic hypertension...
in 31 patients, coronary heart disease in 16, and carotid artery disease in eight. Moreover, nine patients had a prior history of glaucoma. Mean initial intraocular pressure was 15.5 mm Hg (range = 7–24 mm Hg), and on discharge this was 21.5 mm Hg (range = 11–50 mm Hg) (n = 32). Paracentesis was performed in only three cases after the injection to reverse post-injection ocular hypertension and to facilitate retinal perfusion as assessed by indirect ophthalmoscopy (two eyes had neovascular glaucoma, and one eye had central retinal artery occlusion at a post-injection pressure of 21 mm Hg).

The major ocular conditions under therapy included diabetic retinopathy in 39 patients (21 with proliferative retinopathy and twelve with background retinopathy), wet age-related macular degeneration in 25, and retinal venous occlusion in 18 (13 central and five branch varieties). The ocular vascular events registered were ocular vascular occlusions (of an unspecified type in 30 cases), ipsilateral central retinal artery occlusion (19 cases), contralateral central retinal artery occlusion (one case), branch retinal artery occlusion (four cases), unspecified retinal artery occlusion (14 cases), ophthalmic artery occlusion (two cases), choroidal ischemia (one case), retinal capillary occlusion (31 cases, 19 of which were causing macular ischemia), central retinal vein occlusion (three cases), branch retinal vein occlusion (four cases), unspecified retinal vein occlusion (twelve cases), retinal artery spasm (two cases), anterior ischemic optic neuropathy (16 cases), ischemic optic neuropathy (four cases), and one case of vision loss of unspecified origin (Tables 1 and 2).

The median follow-up time in 48 patients was 3 months (average = 8 months; range = 1–36 months). Mean visual acuity (log Mar) dropped by 6.4 lines from 0.85 (20/142; median = 0.7) to 1.49 (20/618; median = 1.0) (Student’s t-test n = 62; P = 0.0002). 40 eyes lost vision, ten eyes maintained vision, and 15 eyes gained vision at the last carried examination. Severe visual loss after injection to no light perception (NLP) occurred in five eyes, light perception (LP) in six eyes, and hand motion (HM) in three eyes.

Ocular vascular events occurred during anti-VEGF therapy in eight of 42 of patients (19.0%) in this selective prospective study. Overall in 26 centers, 55 ocular vascular events were reported among a total of 51,152 patients (0.108%) that received intravitreal anti-VEGF therapy (Tables 1 and 2). Eight ocular vascular events were reported in five centers among a total of 5340 patients (0.149%) that received intravitreal bevacizumab therapy. In the subset of the population who were diabetic, 15 ocular vascular events were reported in four centers from a total of 575 patients (2.61%; Tables 1 and 2). In one center, two cases of retinal vascular occlusions followed intravitreal VEGF antagonists from a total of 300 retinovascular occlusion cases examined. In a double blind randomized prospective study, two patients (2%) developed retinovascular events among 102 diabetics with macular edema treated with intravitreal ranibizumab, while there were no events reported in the control group.30 Terui et al37 described the occurrence of capillary nonperfusion in four out of 58 eyes (6.9%) with branch retinal vein occlusion 1 month after intravitreal bevacizumab (note that this was minimal in three eyes and marked in one); it is unknown if this is related to the injection or part of the natural history of the ocular disease.

Retinal vasoconstriction was observed after both bevacizumab and ranibizumab injections. More specifically, vasoconstriction analyses were available in 13 of the submitted 20 eyes (seven eyes did not meet the requirements for a paired comparison; Table 3). Vasoconstriction was measured between 7 and 30 days (median = 14 days) after injection of bevacizumab (1.25 mg) in 13 eyes. Mean retinal arterial constriction was 21% (standard deviation = 27%) and mean venous constriction was 8% (standard deviation = 30%). Four cases had prominent retinal arterial vasoconstriction of 78%, 57%, 54%, and 28%, while a fifth eye had 33% retinal venous constriction. Vasoconstriction was also measured in one eye that had intravitreal ranibizumab (0.5 mg), with 42% retinal arterial constriction and 16% retinal venous constriction reported.

Discussion

The adverse events associated with systemic bevacizumab include hypertension, proteinuria, and thromboembolism.34,47 Mourad et al used intravital video microscopy to measure dermal capillary densities in the dorsum of the fingers of patients receiving systemic bevacizumab and showed endothelial dysfunction and rarefaction by laser Doppler flowmetry.36 The ocular vascular effects of VEGF antagonists are still unclear. Costa et al evaluated the safety of intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion, with no complications noted at the 25-week follow-up in seven patients.48 Neubauer et al tried to assess peripheral perfusion before and after intravitreal bevacizumab and described a significant improvement in retinal perfusion post injection in 19 patients with nonproliferative diabetic macular edema.9 Chung et al found no visual improvement in eyes with diabetic macular ischemia after intravitreal bevacizumab, and
Table 1 Collaborative and literature review of 106 cases of ocular vascular complications of the VEGF antagonist bevacizumab: clinical profile

| Case N./sex/age | Ocular vascular event after | Dose used (mL) | Paracentesis | IOP at discharge post injection | Prior IOP | Glaucoma | Primary eye disease |
|-----------------|----------------------------|----------------|--------------|--------------------------------|-----------|----------|---------------------|
|                 |                            |                |              |                                |           |          |                     |
| **Arterial occlusion** |                           |                |              |                                |           |          |                     |
| 1/F/60          | CRAO                       | Bevacizumab 2.5 mg | No           | 30                              | 15        | No       | Ischemic CRVO/PDR/serous macular elevation |
| 2/F/74          | CRAO                       | Bevacizumab 1.25 mg | No           | NA                              | 10        | No       | Ischemic CRVO/serous macular elevation |
| 3/F/95          | CRAO                       | Bevacizumab 1.25 mg | No           | NA                              | 7         | No       | AMD                 |
| 4/M/49          | CRAO                       | Bevacizumab 1.25 mg | Yes          | 14 before tap                    | 14        | No       | PDR/DM               |
| 5/F/47          | CRAO                       | Bevacizumab 1.25 mg | No           | 14                              | 16        | No       | PDR/vitreous hemorrhage |
| 6/M/70          | CRAO                       | Bevacizumab 1.25 mg | No           | NA                              | 12        | Yes      | CRVO                 |
| 7/F/56          | CRAO                       | Bevacizumab 1.25 mg | No           | NA                              | NA        | No       | CRVO                 |
| 8/F/60          | CRAO                       | Bevacizumab 2.5 mg | No           | NA                              | 17        | No       | AMD                 |
| 9/M/73          | CRAO                       | Bevacizumab 1.25 mg | No           | NA                              | 19        | 20       | No                   |
| 10/F/72         | CRAO                       | Bevacizumab 1.25 mg | No           | 19                              | 20        | No       | AMD                 |
| 11/74/F         | CRAO                       | Bevacizumab 1.25 mg | No           | <25                             | <25       | No       | DM                  |
| 12/52/F         | CRAO                       | Bevacizumab 1.25 mg | No           | 20 mmHg                         | 20 mmHg   | Yes      | NVG                 |
| 13/F/60         | CRAO                       | Bevacizumab      | NA           | NA                              | NA        | NA       | NA                  |
| 14/F/60<sup>1</sup> | CRAO                       | Bevacizumab 1.25 mg | Yes          | 50                              | 20        | Yes      | PDR/NVG              |
| 15/F<sup>2</sup> | CRAO                       | Bevacizumab      | NA           | NA                              | NA        | NA       | NA                  |
| 16/M/78         | Contralateral CRAO         | Bevacizumab 1.25 mg | NA           | NA                              | NA        | NA       | AMD                 |
| 17/M/44         | BRAO                       | Bevacizumab 1.25 mg | No           | NA                              | 28        | 12       | No                   |
| 18/M/76         | BRAO                       | Bevacizumab 1.25 mg | No           | 16                              | 16        | No       | AMD                 |
| 19/M/45         | BRAO                       | Bevacizumab systemic | No           | 16                              | 16        | No       | None                |
| 20/F/53<sup>2</sup> | BRAO                       | Bevacizumab 1.25 mg | NA           | NA                              | NA        | NA       | PDR                 |
| 21/M/65         | Retinal artery occlusion   | Bevacizumab     |              |                                 |           |          |                     |
| 22/4/M/80       | Retinal artery occlusion   | Bevacizumab 2.5 mg |              |                                 |           |          | DR                  |
| 23/F/60         | Retinal artery occlusion   | Bevacizumab     |              |                                 |           |          | Yes                 |
| 24/F/x          | Retinal artery occlusion   | Bevacizumab 15mg/kg q 3wk |            |                                 |           |          |                     |

<sup>1</sup> Intracameral.

<sup>2</sup> In addition to systemic anti-VEGF injection.

... (Continued)
Table 1

Collaborative and literature review of 106 cases of ocular vascular complications of the VEGF antagonist bevacizumab: clinical profile

| Interval injection to detection of vascular occlusion (days) | N. prior injections | OD or OS | Visual acuity prior to vascular event (log MAR) | Visual acuity after vascular event (log MAR) | Follow up after ocular event (months) | Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients) |
|-------------------------------------------------------------|---------------------|----------|-----------------------------------------------|--------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------|
| 5                                                          | 1                   | OD       | CF3m (1.6)                                    | 20/60 (0.5)                                | 4                                   | HTN, DM, carotid stenosis 1/19,158                                                                 |
| 14                                                         | 1                   | OD       | CF0.3m (2.5)                                  | CF0.3m (2.5)                               | 1                                   | Smoker, 1/19,158                                                                                   |
| 28                                                         | 4                   | OD       | 20/50 (0.4)                                   | LP (3.3)                                   | 5                                   | HTN, CAD 1/19,158                                                                               |
| 0                                                          | 1                   | OS       | 20/160 (0.9)                                  | NLP (3.6)                                  |                                      | DM 1/19,158                                                                                        |
| 45                                                         | 1                   | OD       | 20/200 (1)                                    | HM (3)                                      |                                      | DM, 1/2,000                                                                                        |
| 30                                                         | 1                   | NA       | 20/200 (1)                                    | CF0.3m (2.5)                               |                                      | HTN, 1/2,400 bevacizum                                                                            |
| 30                                                         | 1                   | NA       | 20/80 (0.6)                                   | HM (3)                                      |                                      | None, 1/2,400 bevacizum                                                                            |
| 14                                                         | 0                   | OD       | 20/20 (0.0)                                   | HM (3)                                      | 6                                   | HTN, Smoker, 1/6,478 anti-VEGF                                                                    |
| 15                                                         | 1                   | OD       | 20/100 (0.7)                                  | 20/400 (1.3)                                | 15                                  | HTN, Smoker, CAD, 1/6,478 anti-VEGF                                                               |
| 10                                                         | 1                   | OD       | 20/160 (0.9)                                  | 20/250 (1.1)                                | 18                                  | HTN, Smoker, 1/6,478 anti-VEGF, CAD                                                               |
| 2                                                          | 3                   | NA       | CF (1.6)                                       | NLP (3.6)                                   |                                      | DM/CAD, 1/6,478 anti-VEGF                                                                         |
| 1                                                          | 1                   | NA       | 20/200 (1)                                    | NLP (3.6)                                   |                                      | DM/HTN, 1/400 bevacizum                                                                          |
| NA                                                         | NA                  | NA       | 20/1000 (1.7)                                 | LP (3.3)                                    | 12r                                 | DM, 1/400 bevacizum                                                                              |
| 7                                                          | NA                  | NA       | NA                                            | NA                                         |                                      | 1/5.228                                                                                            |
| 21                                                         | 0                   | NA       | CF0.3m (2.5)                                  | CF1m (2)                                    | 3                                   | Hypercholesterolemia, CAD post coronary bypass 3/2,400 bevacizum, HTN 1/2,400 anti-VEGF          |
| 2                                                          | 1                   | OD       | 20/125 (0.8)                                  | CF2m (1.8)                                  | 9                                   | HTN, DM, CAD, Smoker, 1/19,158                                                                   |
| NA                                                         | 13                  | OD       | 20/400 (1.3)                                  | 20/50 (0.4)                                 | 24                                  | DM, CAD, Smoker                                                                                 |
| 1                                                          | 1                   | OS       | 20/100 (0.7)                                  | 20/50 (0.4)                                 | 3                                   | HTN, cancer                                                                                      |
| 14                                                         | 1                   | OS       | 20/50 (0.4)                                   | 20/600 (1.5)                                | 1                                   | DM, 1/12 PDR patients Avastin Side Effects Report: 5096382-0 DM Avastin Side Effects Report: 5105228-3 Avastin Side Effects Report: 5536025-2 Lung cancer on Navelbine Avastin Side Effects Report: 5593981-4 |

(Continued)
| Case N./sex/age | Ocular vascular event after | Dose used (mL) | Paracentesis | IOP at discharge post injection | Prior IOP | Glaucoma | Primary eye disease |
|----------------|-----------------------------|----------------|--------------|---------------------------------|-----------|----------|-------------------|
| 25/M/x         | Retinal artery occlusion    | Bevacizumab 1.25 mg | No           | 29                              | 15        | Yes      | AMD               |
| 26/M/44        | Retinal artery occlusion    | Bevacizumab 1.25 mg | No           | 29                              | 15        | Yes      | Retinal vein occlusion |
|                | **Venous occlusion**        |                |              |                                 |           |          |                   |
| 27/M/93        | CRVO                        | Bevacizumab 1.25 mg | No           | 29                              | 15        | Yes      | AMD               |
| 28/M/50        | CRVO                        | Bevacizumab systemic | NA           | NA                              | NA        | NA       | None              |
| 29/F/65        | CRVO-like picture           | Bevacizumab 1.25 mg | No           | NA                              | NA        | No       | PDR               |
| 30/F/79        | BRVO                        | Bevacizumab 1.25 mg | No           | 32                              | 11        | No       | AMD               |
| 31/M/65        | BRVO                        | Bevacizumab 1.25 mg | No           | 22                              | 16        | No       | PDR/ischemic DM/vitreous hemorrhage |
| 32/M/63        | BRVO                        | Bevacizumab 1.25 mg | No           | 24                              | 16        | No       | PDR/ischemic DM   |
| 33/premature baby | Inferior retinal vein sheathing (nonperfusion) | Bevacizumab 0.625 mg | NA           | NA                              | NA        | No       | Retinopathy of prematurity |
| 34/F           | Retinal vein occlusion      | Bevacizumab 1.25 mg | NA           | NA                              | NA        | NA       | AMD               |
| 35/F           | Retinal vein occlusion      | Bevacizumab 1.2 mg  | NA           | NA                              | NA        | NA       | AMD               |
| 36/M/90        | Retinal vein occlusion (ischemic) | Bevacizumab 1.25 mg | No           | 29                              | 15        | Yes      | AMD               |
| 37/F/x         | Retinal vein occlusion (ischemic) | Bevacizumab 1.25 mg | No           | 29                              | 15        | Yes      | DR/AMD            |
| 38/F/x         | Retinal vein occlusion      | Bevacizumab 1.25 mg | No           | 29                              | 15        | Yes      | DR/AMD            |
| 39/F/27        | Retinal vein occlusion      | Bevacizumab      | No           | 29                              | 15        | Yes      | Retinal neovascularization |
| 40/F/73        | Retinal vein occlusion      | Bevacizumab 350 mg q2wk | No           | 29                              | 15        | Yes      | Retinal neovascularization |
| 41/F/x         | Retinal vein occlusion      | Bevacizumab      | No           | 29                              | 15        | Yes      | CME               |
| 42/M/69        | Retinal vein occlusion      | Bevacizumab 1000 mg q3wk | No           | 29                              | 15        | Yes      | CME               |
| 43/M/72        | Retinal vein occlusion      | Bevacizumab      | No           | 29                              | 15        | Yes      | CME               |
| Interval injection to detection of vascular occlusion (days) | N. prior injections | OD or OS | Visual acuity prior to vascular event (log MAR) | Visual acuity after vascular event (log MAR) | Follow up after ocular event (months) | Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients) |
|-------------------------------------------------------------|--------------------|---------|-----------------------------------------------|--------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| 10                                                          | 1                  | OD      | 20/60 (0.5)                                   | 20/400 (1.3)                                | 18                               | Avastin Side Effects Report: 5736856-X, 5746319-3 Avastin Side Effects Report: 6237313-7, 6237504-5, 6253539-0, 6253542-0, 6341872-3, 6358564-7 |
| 1 day after each cycle                                       | NA                 | OD      | 20/120 (0.8)                                  | NA                                         |                                  | Metastatic adenocarcinoma of colon after 2 cycles of capecitabine, oxaliplatin and bevacizumab                                  |
| 7                                                           | 0                  | OD      | 20/400 (1.3)                                  | 20/200 (1)                                  | 9                                | DM                                                                                 |
| 55                                                          | 1                  | OS      | 20/30 (0.2)                                   | 20/30 (0.2)                                 | 18                               | HTN, CAD (stent; pacemaker) Left carotid artery disease 1/19,158                                                                   |
| 7                                                           | 0                  | OS      | CF2m (1.8)                                    | 20/200 (1)                                  | 3                                | HTN, DM                                                                            |
| 7                                                           | 0                  | OD      | CF4m (1.5)                                    | 20/80 (0.6)                                 | 3                                | DM                                                                                 |
| 3                                                           | 0                  | OU      | NA                                            | NA                                         |                                  | Retinopathy of prematurity 1/40 patients with retinopathy of prematurity                                                           |
| NA                                                          | NA                 | NA      | NA                                            | NA                                         |                                  | 1/300 of wet AMD                                                                   |
| NA                                                          | NA                 | NA      | NA                                            | NA                                         |                                  | 1/300 of wet AMD                                                                   |

(Continued)
| Case N./sex/age | Ocular vascular event after | Dose used (mL) | Paracentesis | IOP at discharge post injection | Prior IOP | Glaucoma | Primary eye disease |
|----------------|-----------------------------|----------------|--------------|--------------------------------|-----------|----------|---------------------|
| **Retinal vascular occlusion (unspecified)** | | | | | | | |
| 44/M/43 | Retinal vascular disorder | Bevacizumab 1 mg | No | NA | 12 | No | AMD; fellow eye AION |
| 45/M/41 | Retinal vascular disorder | Bevacizumab 1 mg | No | NA | 20 | No | AMD |
| 46/F/x | Retinal vascular disorder | Bevacizumab 1 mg | No | NA | 23 | Yes | DM |
| 47/M/x | Retinal vascular disorder | Bevacizumab 1 mg | No | NA | 21 | 20 | DM |
| 48/F/x | Retinal vascular disorder | Bevacizumab 1 mg | No | NA | 16 | 20 | AMD |
| 49/M/75 | Retinal vascular disorder | Bevacizumab 1 mg | No | NA | 23 | Yes | DM |
| 50/F/33 | Retinal vascular disorder | Bevacizumab | No | NA | 21 | 20 | DM |
| 51-59/9 cases above 40 years | Retinal vascular disorder | Bevacizumab | No | NA | 21 | 20 | DM |
| **Optic neuropathy** | | | | | | | |
| 60/F/72 | AION | Bevacizumab 1.25 mg | No | NA | 12 | No | AMD; fellow eye AION |
| 61/F/71 | AION | Bevacizumab 1.25 mg | No | NA | 16 | 20 | No | AMD |
| 62/M/51 | AION | Bevacizumab 1.25 mg | No | NA | 23 | Yes | DM |
| 63/F/38 | AION | Bevacizumab 1.25 mg | No | NA | 21 | 20 | DM |
| 64/F/70 | AION | Bevacizumab 1.25 mg | No | NI | NI | No | AMD |
| 65/M/86 | AION | Bevacizumab 2.5 mg | No | NA | 20 | NA | AMD |
| 66/F/92 | AION | Bevacizumab 2.5 mg | No | NA | 20 | No | AMD |
| 67/M/70 | AION | Bevacizumab 1.25 mg | No | NA | 3 | No | AMD |
| 68/M/x | AION | Bevacizumab 10 mg/kg | No | NA | 20 | No | AMD |
| 69/F/x | AION | Bevacizumab 394 mg days 1 and 15 | No | NA | 12 | No | AMD |
| 70/F/x | AION | Bevacizumab 1.25 mg | No | NA | 20 | No | AMD |
| 71/F/72 | AION | Bevacizumab | No | NA | 20 | No | AMD |
| 72/F/47 | Optic neuropathy | Bevacizumab systemic monthly | NA | NA | NA | NA | Glioblastoma right frontotemporal |
| 73/M/x | Optic neuropathy | Bevacizumab systemic | NA | NA | NA | NA | Glioblastoma |
| 74/F/67* | Optic neuropathy | Bevacizumab systemic | NA | NA | NA | NA | Glioblastoma |
| 75/F/59* | Optic neuropathy | Bevacizumab systemic | NA | NA | NA | NA | Glioblastoma |
| **Capillary occlusion** | | | | | | | |
| 76/F/58 | Macular ischemia | 1.25 mg Bevacizumab | No | NI | NI | No | Background DR |
| 77/F/73 | Macular ischemia | Bevacizumab 1.25 mg | No | NA | 20 | No | Pre-PDR |
| Interval injection to detection of vascular occlusion (days) | N. prior injections | OD or OS | Visual acuity prior to vascular event (log MAR) | Visual acuity after vascular event (log MAR) | Follow up after ocular event (months) | Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients) |
|-------------------------------------------------------------|--------------------|----------|-----------------------------------------------|---------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------|
| 7                                                          | 1                  | OS       | CF2m (1.8)                                     | LP (3.3)                                    | 0.5                                  | none 1/2,100 bevacizumab                                                      |
| 60                                                         | 1                  | OS       | 20/70 (0.55)                                  | 20/70 (0.55)                                | 6                                   | HTN 1/333                                                                     |
| 15                                                         | 1                  | OD       | 20/25 (0.1)                                   | 20/25 (0.1)                                 | 12r                                 | Pseudoxanthoma elasticum                                                      |
| 21                                                         | 0                  | OS       | 20/40 (0.3)                                   | 20/25 (0.1)                                 | 14                                  | DM 1/150 bevacizumab                                                          |
| 28                                                         | 3                  | OD       | 20/60 (0.5)                                   | 20/120 (0.8)                                | 6                                   | None 1/500 bevacizumab                                                        |
| 30                                                         | 14                 | OD       | 20/70 (0.55)                                  | 20/100 (0.7)                                | 12                                  | HTN, prostate cancer, esophageal cancer, on amlodipine 1/6000 injection anti-VEGF |
| 8                                                          | OS                 |          | 20/70 (0.55)                                  | 20/100 (0.7)                                | 48                                  | No significant past medical history, on no medications                       |
| 34                                                         | OS                 |          | 20/70 (0.55)                                  | 20/200 (1.0)                                | 6                                   | No significant past medical history, on aspirin                              |
|                                                             |                    |          |                                               |                                             |                                      | Visual acuity reduced                                                         |

2 years after initial injection

| 2 (monthly) | OU | 20/200 (1) (amblyopia) OD 20/70 (0.55) OS | LP OD (3.3) NLP (3.6) OS | 30 |
|-------------|----|------------------------------------------|--------------------------|----|
| NA          | 8  | NA                                       | NA                       |    |
| NA          | 6  | NA                                       | NA                       |    |
| NA          | 7  | NA                                       | NA                       |    |
| 2           | 1  | 20/60 (0.5)                              | 20/400 (1.3)              | 12 |
| 42          | 0  | 20/80 (0.6)                              | 20/80 (0.6)               | 3  |

DM 1/2,350 anti-VEGF
DM HTN 1/53 retrospective study of BRVO and diabetic maculopathy

(Continued)
| Case N./sex/age | Ocular vascular event after | Dose used (mL) | Paracentesis | IOP at discharge post injection | Prior IOP | Glaucoma | Primary eye disease |
|----------------|----------------------------|---------------|--------------|-------------------------------|-----------|---------|---------------------|
| 78/F/72        | Macular ischemia           | Bevacizumab 1.25 mg | No           | NA                            | NA        | No      | BRVO                |
| 79/M/66        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 16                            | 10        | Yes     | CRVO/pre-PDR        |
| 80/F/37        | Macular ischemia           | Bevacizumab 1.25 mg | NA           | NA                            | NA        | No      | Vasculitis           |
| 81/M/40        | Macular ischemia           | Bevacizumab 2.5 mg | NA           | NA                            | NA        | No      | PDR                 |
| 82/F/76        | Macular ischemia           | Bevacizumab 1.25 mg | NA           | NA                            | NA        | No      | CRVO ischemic       |
| 83/M/74        | Macular ischemia           | Bevacizumab 1.25 mg | NA           | NA                            | NA        | NA      | CRVO ischemic       |
| 84/M/58        | Macular ischemia           | Bevacizumab 1.25 mg | No           | NA                            | NA        | No      | DM                  |
| 85/F/58        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 20                            | 14        | No      | PDR/diffuse DM      |
| 86/F/60        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 18                            | 14        | No      | PDR/diffuse DM      |
| 87/M/64        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 20                            | 16        | No      | PDR/diffuse DM/ vitreous hemorrhage |
| 88/F/65        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 22                            | 14        | No      | PDR/diffuse DM      |
| 89/M/64        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 18                            | 14        | No      | PDR/ischemic DM     |
| 90/M/52        | Macular ischemia           | Bevacizumab 1.25 mg | No           | 24                            | 18        | No      | PDR/diffuse DM      |
| 91/M/70        | Hemorrhagic macular infarction; worsening CRVO | Bevacizumab 1.25 mg | NA | NA | 15 | No | CRVO |
| 92/M/65        | Conversion of nonischemic CRVO into ischemic CRVO | Bevacizumab 1.25 mg | NA | NA | NA | NA | CRVO |
| 93             | Capillary occlusion Cotton wool spot | Bevacizumab intravitreal | | | | | |
| 94             | Capillary ischemia         | Bevacizumab 1.25 mg | No           | NA                            | NA        | No      | Nonischemic BRVO    |
| 95             | Capillary ischemia         | Bevacizumab 1.25 mg | No           | NA                            | NA        | No      | Nonischemic BRVO    |
| 96             | Capillary ischemia         | Bevacizumab 1.25 mg | No           | NA                            | NA        | No      | Nonischemic BRVO    |
| 97/F/62        | Capillary ischemia         | Bevacizumab 1.25 mg | No           | NA                            | NA        | No      | Ischemic BRVO       |
| 98             | Retinal ischemia           | Bevacizumab 1.25 mg | NA           | NA                            | NA        | No      | CRVO                |
| 99/M/66        | Capillary occlusion Cotton wool spot | Bevacizumab 1.25 mg | No | 14 | 24 | No | AMD |
| 100/F/74       | Capillary occlusion Cotton wool spot | Bevacizumab 1.25 mg | No | 11 | 23 | No | Idiopathic foveal telangiectasia |
| 101/F/27       | Capillary occlusion Cotton wool spot | Bevacizumab 1.25 mg | No | NA | NA | No | Retinal vasculitis |
| Interval injection to detection of vascular occlusion (days) | N. prior injections | OD or OS | Visual acuity prior to vascular event (log MAR) | Visual acuity after vascular event (log MAR) | Follow up after ocular event (months) | Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients) |
|-------------------------------------------------------------|---------------------|----------|-----------------------------------------------|---------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------|
| 28                                                          | 0                   | OS       | 20/60 (0.5)                                   | 20/80 (0.6)                                  | 2                                    | DM                                                                                                   |
| 4                                                           | 1                   | OS       | 20/100 (0.7)                                  | 20/220 (1.0)                                 | 30                                   | DM 1/53 retrospective study of BRVO and diabetic maculopathy                                      |
| 7                                                           | 1                   | OS       | 20/50 (0.4)                                   | 20/125 (0.8)                                 | 1                                    | DM None                                                                                              |
| NA                                                          | 0                   | OS       | 20/400 (1.3)                                  | 20/400 (1.3)                                 | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 28                                                          | 1                   | OD       | 20/200 (1)                                    | 20/200 (1)                                   | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 28                                                          | 2                   | OS       | 20/100 (0.7)                                  | 20/200 (1)                                   | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 21                                                          | 0                   | OD       | 20/80 (0.6)                                   | 20/200 (1)                                   | 6                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 7                                                           | 0                   | OD       | 20/200 (1)                                    | 20/80 (0.6)                                  | 3                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 7                                                           | 0                   | OS       | 20/200 (1)                                    | 20/120 (0.8)                                 | 3                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 7                                                           | 0                   | OD       | CF3m (1.6)                                    | 20/80 (0.6)                                  | 3                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 7                                                           | 0                   | OS       | 20/120 (0.8)                                  | 20/80 (0.6)                                  | 3                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 7                                                           | 0                   | OD       | 20/200 (1)                                    | 20/120 (0.8)                                 | 3                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 21                                                          | 0                   | OS       | 20/100 (0.7)                                  | 20/320 (1.2)                                 | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 21                                                          | 1                   | OD       | 20/50 (0.4)                                   | 20/800 (1.6)                                 | 6                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| I month                                                     | 0                   | NA       | NA                                            | NA                                          | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| I month                                                     | 0                   | NA       | NA                                            | NA                                          | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| I month                                                     | 0                   | NA       | NA                                            | NA                                          | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| I month                                                     | 0                   | OS       | 20/120 (0.8)                                  | 20/200 (1.0)                                 | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 30                                                          | 1                   | OS       | 20/200 (1)                                    | 20/200 (1)                                   | 36                                   | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 60                                                          | 1                   | OS       | 20/80 (0.6)                                   | 20/70 (0.55)                                 | 36                                   | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |
| 14                                                          | 1                   | OU       | 20/20 (0)                                     | 20/20 (0)                                    | 1                                    | DM DM CVA 1/300 of retinal vascular occlusion cases                                                  |

(Continued)
Evidence suggests that vessel diameter is influenced by the drug.\textsuperscript{51–53} Retinal arteriolar diameter decreased by 4.6% ± 4.6% at day 7 and by 8.1% ± 3.2% at day 30 in eleven eyes with neovascular macular degeneration after treatment with intravitreal ranibizumab.\textsuperscript{51} Similarly, 1 month after ranibizumab was injected into ten eyes with macular degeneration, Mendrinos et al found a mean arterial vasoconstriction of 8.4% ± 3.2%.\textsuperscript{52} Sacu et al found significant retinal arterial and venous vasoconstriction with a significant reduction in retinal perfusion in 27 patients with retinal branch vein occlusion.\textsuperscript{53} Soliman et al used bevacizumab to treat ten eyes with diffuse diabetic macular edema, and found that the most pronounced changes in vessel diameter occurred in two patients with proliferative diabetic retinopathy.\textsuperscript{5} We measured a higher vasoconstrictor effect and some eyes had marked vasoconstriction. It is also possible that there is a shift from vessel dilation driven by ischemia to constriction induced by VEGF antagonists, hence the large constrictive response which is reported.

Treatmen with intravitreal VEGF antagonists is accompanied by exacerbation of systemic hypertension\textsuperscript{54} and attenuation of systemic VEGF levels.\textsuperscript{55} This effect on the vascular tone may last for 3 weeks following intravitreal injections.\textsuperscript{54–56} but Lee et al found that only 30-minute systolic values were significantly higher than baseline blood pressure after bevacizumab injection.\textsuperscript{56} It is possible that this acute rise in blood pressure may be related to the stress of the intravitreal injection. Some patients have a panic attack during the injection, others get hyperglycemia,\textsuperscript{57} while a few may develop a dendritic corneal ulcer following treatment.\textsuperscript{58} Transient ocular hypertension after intravitreal injection of VEGF antagonists has been emphasized in many studies.\textsuperscript{59–62} Persistent ocular hypertension is of recent concern and occurs in around 3.4% of eyes, usually following multiple injections.\textsuperscript{62} This may relate to the presence of silicone oil or other large particulate matter in the syringe, such as high molecular weight aggregates in repackaged bevacizumab. A considerable short-term rise in intraocular pressure occurs preferentially in hyperopic eyes\textsuperscript{60,62} and eyes with known glaucoma, so there is a need to monitor intraocular pressure and retinal perfusion especially in eyes with poor retinal circulation.\textsuperscript{18} Acute angle closure glaucoma may also be precipitated by intravitreal injections.\textsuperscript{62}

The risk of ocular vascular events during anti-VEGF therapy was 0.108% in the treatments considered in the current study. The low rate and the large variation in the occurrence of such events among the collaborating centers may be related to several factors including the retrospective nature of the study, the ocular pathology bias, the natural history of ocular disease, and the absence of precisely scheduled fluorescein angiographic studies. Performing detailed eye examinations with fundus photography and fluorescein angiography initially, at 1 week,
and 1 month post-injection in a prospective setting (such as in the prospective study from Mansoura University) yielded higher rates of ocular events than were reported following retrospective quick screening examinations at the time of repeated injections. Many of the reported events were asymptomatic, such as capillary occlusion outside the fovea, and minor branch retinal artery or vein occlusion. In the RESOLVE study, a total of 102 cases having ranibizumab injections for diabetic maculopathy resulted in two cases with retinal vascular events (capillary and arterial occlusions).\textsuperscript{30} In the ROCC study, one of the 16 patients with central retinal vein occlusion developed central retinal artery occlusion.\textsuperscript{63} Branch retinal artery occurred in one out of twelve consecutive patients with proliferative diabetic retinopathy following intravitreal bevacizumab.\textsuperscript{32} In the ANCHOR\textsuperscript{64} and MARINA\textsuperscript{65} studies (280 and 477 patients, respectively), no retinal vascular events were noted after 2 years of repeated intravitreal ranibizumab for the wet form of age-related macular degeneration. Prior prospective studies and the current survey showed that eyes with wet age-related macular degeneration had the lowest frequencies of vascular events (0%–0.3%)\textsuperscript{66,67} while eyes with a greater number of ischemic vascular diseases such as proliferative diabetic retinopathy yielded a higher frequency of retinal vascular events (2%–19%, as in the current prospective study).\textsuperscript{30} The occurrence of ocular vascular occlusions after anti-VEGF medications was 2.61% in the diabetic population (Tables 1 and 2), almost 24 times the occurrence in the general population receiving VEGF antagonists (Tables 1 and 2).

Three studies show choroidal or retinal vaso-occlusion after intravitreal bevacizumab injections in experimental animals. Peters et al analyzed the acute intravitreal effects of bevacizumab in four cynomolgus monkeys and found that choriocapillaris endothelial cell fenestrations were significantly reduced, and that densely packed thrombocytes and leukocytes regionally occluded the choriocapillaris lumen of treated eyes.\textsuperscript{66} Schraermeyer et al found that bevacizumab immune complexes activate platelets and cause thrombosis in choroidal vessels of primate eyes.\textsuperscript{67,68} Ameri et al evaluated the effects of intravitreal bevacizumab in a rabbit retinal neovascularization model. An intravitreal VEGF injection was administered and intravitreal bevacizumab was then injected at day 2 and at week 1, and it was found that administration of intravitreal bevacizumab at week 1 resulted in severe capillary nonperfusion at week 2.\textsuperscript{69} Bonnin et al demonstrated ocular hypoperfusion after intravitreal bevacizumab in humans. In 15 patients with wet age-related macular degeneration, mean blood flow velocities were measured by ultrasound imaging before, and 4 weeks after, a single intravitreal injection of bevacizumab. Velocities decreased significantly in the central retinal, temporal posterior ciliary, and ophthalmic arteries by 10%, 20%, and 20% respectively.\textsuperscript{68,70} Sacu et al found significant vasoconstriction of retinal arteries and veins outside the area of nonischemic retinal branch vein occlusions as well as a
Table 2 Collaborative and literature review of 38 cases of ocular vascular complications of VEGF antagonists excluding bevacizumab (ranibizumab and pegaptanib): clinical profile

| Case N./sex/age | Ocular vascular event after | Dose used (mL) | Paracentesis | IOP at discharge post injection | Prior IOP | Glaucoma | Primary eye disease |
|-----------------|----------------------------|----------------|--------------|---------------------------------|-----------|----------|-------------------|
| Arterial occlusion | CRAO | Ranibizumab 0.5 mg | No | Nl | NA | No | Ischemic CRVO |
| 1/M/75 | CRAO | Ranibizumab 0.5 mg | No | 15 | 15 | No | DM |
| 2/M/67 | CRAO | Ranibizumab 0.5 mg | No | 38 mmHg | NA | Yes | NVG |
| 3 | CRAO | Ranibizumab | NA | NA | NA | NA | DM |
| 4/M/85 (Reimao*) | CRAO | Ranibizumab 0.5 mg | No | 38 mmHg | NA | Yes | NVG |
| Retinal artery occlusion | Ranibizumab | | | | | | |
| 5/F/81 | Retinal artery occlusion | Ranibizumab 0.5 mg | | | | | |
| 6/F/x | Retinal artery occlusion | Ranibizumab 0.5 mg | | | | | |
| 7/M/84 | Retinal artery occlusion | Ranibizumab 0.5 mg | | High IOP | | | AMD |
| 8/F/70 | Retinal artery occlusion | Ranibizumab | | | | | |
| 9/F/70 | Retinal artery occlusion | Ranibizumab 0.5 mg | | | | | |
| 10/F/86 | Retinal artery occlusion | Pegaptanib | | | | | |
| 11/M/67 | Retinal artery occlusion | Pegaptanib | | | | | |
| Retinal artery occlusion | Ranibizumab | | | | | | |
| 12/F/above 60 years | Retinal artery occlusion | Ranibizumab | | | | | AMD |
| Venous occlusion | | | | | | | |
| 13/M/84 | Retinal vein occlusion | Ranibizumab 0.5 mg | | | | | |
| 14/M/74 | Retinal vein occlusion | Ranibizumab | | | | | |
| Retinal vascular occlusion (unspecified) | | | | | | | |
| 15/M | Ocular vascular occlusion | Ranibizumab 0.5 mg | NA | NA | NA | NA | DM |
| 16/M | Ocular vascular occlusion | Ranibizumab 0.5 mg | NA | NA | NA | NA | DM |
| 17/M | Ocular vascular occlusion | Ranibizumab 0.5 mg | NA | NA | NA | NA | DM |
| 18/M/47 | Retinal vascular disorder | Ranibizumab 0.3 mg | | | | | CME |
| 19/M/x | Retinal vascular disorder | Ranibizumab | | | | | |
| 20/F/66 | Retinal vascular disorder | Pegaptanib | | | | | AMD |
Table 2  Collaborative and literature review of 38 cases of ocular vascular complications of VEGF antagonists excluding bevacizumab (ranibizumab and pegaptanib): clinical profile

| Interval injection to detection of vascular occlusion (days) | N., prior injections | OD or OS | Visual acuity prior to vascular event (log MAR) | Visual acuity after vascular event (log MAR) | Follow up after ocular event (months) | Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients) |
|-------------------------------------------------------------|---------------------|----------|-----------------------------------------------|---------------------------------------------|--------------------------------------|----------------------------------------------------------------------------------|
| 30                                                         | 1                   | OS       | 20/400 (1.3)                                  | LP (3.3)                                    | 2                                    | DM, CAD 1/2,400 anti-VEGF, 1/16 ROCC study63                                      |
| 30                                                         | 4                   | OS       | 20/100 (0.7)                                  | 20/400 (1.3)                                | 12                                   | DM, HTN 1/6,478 anti-VEGF                                                         |
| NA                                                         | NA                  | NA       | NA                                            | NA                                          | 12                                   | DM, 1/102 eyes prospective study (RESOLVE)                                         |
| 2d                                                         | 0                   | OD       | 20/25 (0.1)                                   | 20/80 (0.6)                                 |                                      | HTN, COPD ex-smoker, bilateral carotid stenosis                                  |
| <1 month                                                   |                     |          |                                               |                                              |                                      | Lucentis Side Effects Report: 6109626-0, HTN, CAD Lucentis Side Effects Report: 6184843-2, Lucentis Side Effects Report: 6210113-X, Lucentis Side Effects Report: 6480905-0, 6496635-5, Lucentis Side Effects Report: 6207699-8, HTN, dyslipidemia Macugen Side Effects Report: 5248582-4, 5224175-X, Macugen Side Effects Report: 6108967-0, 2010 events from eHealthMe drug outcomes from FDA and community Lucentis Side Effects Report: 5216324-4/5889807-1, Lucentis Side Effects Report: 5253885-3/5259058-2                                   |

(Continued)
significant reduction in the flow velocity of the retrobulbar central retinal artery.53

The vascular events reported during VEGF antagonist therapies could be part of the natural history of the underlying ocular disease. A rise in blood pressure, stress of the procedure, the underlying systemic disease, and a sharp rise in intraocular pressure are variables that can be involved in some cases of ocular vascular events, and these variables can be detected and treated. A majority of the patients discussed in the current study had systemic diseases, particularly diabetes mellitus. VEGF antagonism could play a leader role in some cases that demonstrated vasoconstriction by analysis of vessel caliber. VEGF acts as a vessel dilator by stimulating nitric oxide synthesis, and influences the autoregulation.

### Table 2

| Case N./sex/age | Ocular vascular event after | Dose used (mL) | Paracentesis | IOP at discharge post injection | Prior IOP | Glaucoma | Primary eye disease |
|-----------------|-----------------------------|----------------|--------------|---------------------------------|----------|---------|---------------------|
| 21/M/60         | Retinal vascular disorder   | Pegaptanib 0.3 mg |              |                                 | AMD      |         |                     |
| 22/Above 60 years | Retinal vascular disorder   | Pegaptanib |              |                                 | AMD      |         |                     |
| 23–28/6 cases above 60 years | Retinal vascular disorder | Ranibizumab |              |                                 | mixed    |         |                     |
| **Optic neuropathy** |                           |                |              |                                 | AMD      |         |                     |
| 29/M/75         | AION                        | Ranibizumab 0.5 mg |              |                                 | AMD      |         |                     |
| 30/F/70          | AION OU                     | Pegaptanib |              | No                               | NA       | NA      | No AMD OD            |
| 31/M/93         | AION                        | 0.3 mg Pegaptanib |              |                                 |          |         | Diabetic prophylaxis for cataract surgery OS |
| 32/M/72         | AION                        | Pegaptanib |              |                                 | AMD      |         |                     |
| **Capillary occlusion** |                             |                |              |                                 |          |         |                     |
| 33/F/x          | Retinal ischemia (macular)  | Ranibizumab |              |                                 |          |         |                     |
| 34/F/x          | Retinal ischemia (macular)  | Ranibizumab 0.5 mg |              |                                 |          |         |                     |
| 35            | Capillary occlusion (peripheral) | Ranibizumab |              | NA                               | NA       | NA      | DM                  |
| 36/F/x          | Retinal ischemia (peripheral) | Ranibizumab 0.5 mg |              |                                 |          |         |                     |
| 37/above 60 years | Retinal ischemia            | Ranibizumab |              |                                 |          |         | Unspecified         |
| **Miscellaneous** |                             |                |              |                                 |          |         |                     |
| 38/M/85         | Diffuse vascular occlusion  | Ranibizumab 0.5 mg |              | No                               | NA       | 15      | No Ocular ischemic syndrome |

**Notes:** Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe from FDA and community for 2010 and late 2009; *Reimao reference refers to eposter EP-GLA-405 SOE 2011 Genève presented by Reimao P, Macedo M, Gomes M, Maia S, Santos M, Meneses M Jr, from Portugal.

**Abbreviations:** AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column of eye disease); NA, not assessed; Nl, normal; DM, diabetes mellitus; HTN, systemic hypertension; CAD, coronary artery disease; CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy; IOP, intraocular pressure; OD, right eye; OS, left eye; CME, cystoid macular edema; NVG, neovascular glaucoma.
| Interval injection to detection of vascular occlusion (days) | N. prior injections | OD or OS | Visual acuity prior to vascular event (log MAR) | Visual acuity after vascular event (log MAR) | Follow up after ocular event (months) | Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients) |
|-------------------------------------------------------------|---------------------|----------|-----------------------------------------------|-----------------------------------------------|--------------------------------------|-------------------------------------------------------------------------------------------------|
| 4                                                          | OS                  | 20/40    | 20/60                                         | 1                                             | DM                                   | HTN, hypothyroidism, BPH, angina, on amlodipine, levothyroxine, temazepam, nitroglycerin 1/4500 antiVEGF injection |
| 7d OD                                                      | 0                   | OD       | 20/40 (0.3)                                   | 20/4000 (2.2)                                 | 3                                    | DM                                                                                             |
| 4d OS                                                      | OS                  | NA       | 20/200 (1)                                    | 3                                             | DM                                   | HTN                                                                                             |
| NA                                                         | NA                  | NA       | NA                                            | NA                                            | 12                                   | DM /1/102 eyes prospective study (RESOLVE)                                                                 |
| 14                                                        | 1                   | OD       | 20/100 (0.7)                                  | LP (3.3)                                      | 10                                   | Carotid stenosis                                                                                |

in the microcirculation. If we block this rescuer, the retina may be damaged due to decreased retinal perfusion in the presence of a low ophthalmic systolic pressure. Because retinal vessel diameter is a useful surrogate for retinal perfusion, changes in the diameter of the retinal arterioles may indicate changes in retinal capillary blood flow. Thus, these findings suggest that VEGF antagonists may reduce retinal capillary blood flow, and caution should be exercised in the use of intravitreal VEGF inhibitors in eyes with severe ocular ischemia such as ocular ischemic syndrome with low ophthalmic systolic pressure or severe proliferative diabetic retinopathy.11,15 Further studies are needed to evaluate the incidence of vascular events during VEGF antagonist therapy in such high-risk patients.11
| Case/sex/age | Ocular vascular event after | Bevacizumab (mg) | Primary eye disease | Interval injection to last fluorescein angiography (days) | N. prior injections | Systemic disease | Arterial vasoconstriction from baseline 1.0 | Venous vasoconstriction from baseline 1.0 |
|-------------|-----------------------------|------------------|---------------------|-------------------------------------------------|------------------|----------------|--------------------------------|--------------------------------|
| 1/F/74      | CRAO                        | 1.25             | Ischemic CRVO       | 14                                              | 1                | Smoker (heavy) | 0.93                          | 0.68*                               |
| 2/F/27      | Capillary occlusion         | 1.25             | Retinal vasculitis  | 14                                              | 1                | No             | 0.46*                         | 0.73                                |
| 3/M/93      | CRVO                        | 1.25             | CNV                 | 10                                              | 1                | CAD carotid artery disease | 0.90                         | 1.35*                               |
| 4/M/66      | Capillary occlusion CWS    | 1.25             | CNV                 | 30                                              | 1                | Gout           | 0.96                          | 0.84                                |
| 5/M/51      | AION                        | 1.25             | CNV                 | 15                                              | 1                | Pseudoxanthoma elasticum | 0.72*                         | 0.88                                |
| 6/F/76      | Macular ischemia            | 1.25             | CRVO ischemic       | 28                                              | 1                | DM             | 1.03                          | 0.95                                |
| 7/M/74      | Macular ischemia            | 1.25             | CRVO ischemic       | 28                                              | 2                | DM             | 1.03                          | 0.93                                |
| 8/M/65      | BRVO                        | 1.25             | PDR                 | 7                                               | 0                | HTN            | 0.22*                         | 0.67*                               |
| 9/M/63      | BRVO                        | 1.25             | PDR                 | 7                                               | 0                | DM             | 1.01                          | 0.88                                |
| 10/F/60     | Macular ischemia            | 1.25             | PDR                 | 7                                               | 0                | HTN            | 0.43*                         | 0.85                                |
| 11/M/64     | Macular ischemia            | 1.25             | PDR                 | 7                                               | 0                | DM             | 0.83                          | 1.82                                |
| 12/M/64     | Macular ischemia            | 1.25             | PDR                 | 7                                               | 0                | DM             | 1.01                          | 0.88                                |
| 13/M/52     | Macular ischemia            | 1.25             | PDR                 | 7                                               | 0                | DM             | 0.95                          | 0.85                                |
| 14/M/85     | Diffuse vascular occlusion  | 1.25             | Ocular ischemic syndrome | 14                                              | 1                | Carotid stenosis complete | 0.58*                         | 0.84                                |

Notes: Red, intravitreal ranibizumab; *refers to marked constriction; †indicates that this value not counted because it was part of CRVO.
Abbreviations: PDR, proliferative diabetic retinopathy; NA, not assessed; CNV, choroidal neovascularization; DM, diabetes mellitus; HTN, systemic hypertension; CAD, coronary artery disease; MI, myocardial infarction; CVA, cerebrovascular accident; CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy.
Acknowledgments
The Collaborative Anti-VEGF Ocular Vascular Complications Group: K Bailey Freund, Ninel Z Gregori, Nikolaus Feucht, Alay Banker, Therese von Hanno, Claudio Furino, Sabine Aisenbrey, Wael Soliman, Rong-Kung Tsai, Hamid Hosseini, Eric Chen, Hee-Seung Chin, Jane Y Huang, Ali A Bodla, Ozgur Artunay, Vladimir Poposki, Daniel Vilaplana, Michael Larsen, M Tariq Bhatti, Hana A Mansour, Ihab Saab, Hasan Shahine, Zohar Yehoshua, Kara Dellatorre, Shree Kurup.

The authors acknowledge the contribution of Professor FT Fraunfelder who supplied the data from the National Registry of Drug-Induced Ocular Side Effects.

Disclosure
The authors have no financial interests in any product mentioned in the manuscript.

References
1. Liu MH, Jin H, Floten HS, Ren Z, Yim AP, He GW. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery. Ann Thorac Surg. 2002;73(3):819–824.
2. Arenvalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (avastin) for diabetic macular edema. Results from the Pan-American Collaborative Study Group at 6-month follow-up. Ophthalmology. 2007;114(4):743–750.
3. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2008;86(4):365–371.
4. Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010;30(5):781–786.
5. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28(8):1053–1060.
6. Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA Jr, Scott IU. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol. 2009;147(6):1022–1030.
7. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe’s Archive Clin Exp Ophthalmol. 2008;246(1):81–87.
8. Ikuno Y, Soga K, Wakabayashi T, Gomi F. Angiographic changes after bevacizumab. [Letter.] Ophthalmology. 2009;116(11):2263.
9. Neubauer AS, Kook D, Hartiglou D, et al. Bevacizumab and retinal ischemia. [Letter.] Ophthalmology. 2007;114(11):2096.
10. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol. 2010;88(2):263–266.
11. Huang ZL, Lin KH, Lee YC, Shue MM, Tsai RK. Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. Ophthalmologica. 2009;224(2):86–89.
12. Artunay O, Yuzbasioğlu E, Rasier R, Sengul A, Bahcecioglu H. Acute retinal arterial occlusion after intravenous administration of bevacizumab. BMJ Case Rep. 2009;1:1478.
13. Ganssauge M, Wilhelm H, Bartz-Schmidt KU, Aisenbrey S. Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angiod streaks in pseudoxanthoma elasticum. Graefe’s Archive Clin Exp Ophthalmol. 2009;247(12):1707–1710.
14. Hosseini H, Razeghinia MR. Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab. J Neuroophthalmol. 2009;29(2):160–161.
15. Kofoed PK, Christine Munch IC, Larsen M. Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome. Acta Ophthalmologica. 2010;88(7):808–810.
16. Furino C, Boscia F, Cardascia N, Alessio G, Sborgia C. Hemorrhagic macular infarction after intravitreal bevacizumab for central retinal vein occlusion. Ophthalmol Surg Lasers Imaging. 2010;9:1–2.
17. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2009;40(1):68–70.
18. Mansour AM, Bynoe LA, Welch JC, et al. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol. 2010;88(7):730–735.
19. Huang JY, Ozaki H, Hayashi H, Uchio E. Anterior ischemic optic neuropathy following intravitreal bevacizumab. Jpn J Ophthalmol. 2010;54(3):252–254.
20. Bodla AA, Rao N. Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: is there an association? Indian J Ophthalmol. 2010;58(4):349–350.
21. Kim NR, Chin HS. Progression of impending central retinal vein occlusion to the ischemic variant following intravitreal bevacizumab. Korean J Ophthalmol. 2010;24(3):179–181.
22. Yokoyama K, Chochi T, Kimoto K, Shinoda K, Nakatsuka K. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmologica. 2008;86(8):927–928.
23. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol. 2008;86(8):925–927.
24. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86(4):372–376.
25. Shimura M, Yasuda K. Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease. Br J Ophthalmol. 2010;94(3):381–383.
26. Sabet-Peyman EJ, Heussen FM, Thorne JE, Casparis H, Patel SJ, Do DV. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging. 2009;40(3):316–318.
27. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344–1349.
28. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011;118(1):176–183.
29. Goel N, Kumar V, Ghosh B. Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema. Int Ophthalmol. 2011;31(1):39–42.
30. Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–2405.
31. Yu XR, Wang XZ. Clinical effect for intravitreal injection of avastin for 400 cases fundus disease. International Journal of Ophthalmology. 2010;10:1913–1915.
32. Shin YW, Lee YJ, Lee BR, Cho HY. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol. 2009;23(4):266–272.
33. Battaglia Parodi M, Iacono P, Cascavilla ML, et al. Sequential anterior ischemic optic neuropathy and central retinal artery and vein occlusion after ranibizumab for diabetic macular edema. *Euro J Ophthalmol*. 2010;20(6):1076–1078.

34. Gilbar P, Sorour N. Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection. *J Oncol Pharm Pract*. March 22, 2011. [Epub ahead of print.]

35. Lee SJ, Koh HJ. Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. *Acta Ophthalmologica*. 2008;86(7):812–813.

36. Lee CS, Koh HJ. Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. *Acta Ophthalmologica*. 2008;86(7):812–813.

37. Terui T, Kondo M, Sugita T, et al. Changes in area of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion. *Retina*. 2011;31(6):1068–1074.

38. Kimakura M, Oishi A, Manda M, Kurimoto Y. Bilateral nonarteritic anterior ischemic optic neuropathy following intravitreal injection of pegaptanib. *Clin Exp Ophthalmol*. 2011;22:2–6.

39. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *New Engl J Med*. 2011;364(20):1897–1908.

40. lman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt laser for diabetic macular edema. *Am J Ophthalmol*. 2011;151(1):61–69.

41. Rasier R, Artunay O, Yuzbasigolu E, Sengul A, Babecceoglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. *Eye*. 2009;23(8):1714–1718.

42. Matsuyama K, Ogata N, Matsuoka M, Wada T, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. *Br J Ophthalmol*. 2010;94(9):1215–1218.

43. Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. *Retina*. 2009;29(10):1409–1417.

44. Feldman-Billard S, Chibani A, Héron E. Intravitreal triamcinolone and blood glucose (letter). *Ophthalmology*. 2008;115(5):917.

45. Khalili MR, MehdiZadeh M, Mehray M. Herpetic epithelial keratitis after intravitreal injection of bevacizumab (avastin). *Cornea*. 2009;28(3):360–361.

46. Adelman RA, Zhang Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. *J Ocul Pharmacol Ther*. 2010;26(1):105–110.

47. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. *J Glaucoma*. 2009;18(9):658–661.

48. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of blood pressure and bevacizumab for neovascular age-related macular degeneration. *Clin Exp Ophthalmol*. 2011;2(1):58–60.

49. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. *Am J Ophthalmol*. 2010;150(3):310–314.

50. Rosenfeld PJ, Brown DM, Heier JS, et al. Intravitreal bevacizumab (Avastin®) in neovascular age-related macular degeneration: A randomized sham-controlled trial. *Am J Ophthalmol*. 2009;147(1):173–174.

51. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of blood pressure and bevacizumab for neovascular age-related macular degeneration. *Clin Exp Ophthalmol*. 2011;2(1):58–60.

52. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. *Am J Ophthalmol*. 2010;150(3):310–314.

53. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *New Engl J Med*. 2006;355(14):1419–1431.

54. Schraermeyer U, Schultheiss S, Hofmeister S, Julien S. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2 A transgenic mice. *J Thromb Haemost*. 2009;7(1):57–65.

55. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *New Engl J Med*. 2006;355(14):1419–1431.

56. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. *Am J Ophthalmol*. 2007;143(6):995–1002.

57. Schraermeyer U, Schultheiss S, Hofmeister S, Julien S. Bevacizumab immune complexes activate platelets and cause thrombosis in choroidal vessels of primate eyes. *Invest Ophthalmol Vis Sci*. 2011 (suppl), ARVO Paper No. 5271.

58. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGFR2 A transgenic mice. *J Thromb Haemost*. 2009;7(1):171–181.

59. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. *Invest Ophthalmol Vis Sci*. 2007;48(12):5708–5715.

60. Bonnin P, Pounaras J, Lazarak Z, et al. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin®) in neovascular age-related macular degeneration. *Acta Ophthalmol*. 2010;88(6):641–645.
